GOG Foundation

Research institutionUnited Statesgog.org

The GOG Foundation (GOG) is an independent, non-profit clinical research organization focused on improving outcomes in gynecologic cancers, including ovarian, endometrial, cervical, and vulvar malignancies. The foundation advances patient care by designing, sponsoring, and conducting multi-center clinical trials across academic and community hospitals in the United States and internationally.

Read more

GOG provides scientific leadership and operational infrastructure for phase I–III studies, including protocol development, site activation and monitoring, data management, and analysis. It collaborates with investigators, cooperative groups, and biopharmaceutical companies to evaluate new therapeutics and treatment strategies, and disseminates evidence that informs standards of care and clinical guidelines in gynecologic oncology.

Projects GOG is involved in

None yet. When a new project in the record names GOG as owner, partner or investor, it shows here.

GOG in chemical industry news

20 January 2026
Lilly's Sofetabart Mipitecan Gains FDA Breakthrough Status for Platinum-Resistant Ovarian Cancer

FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.